Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review-Reference-Cited by-同舟云学术

Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review

Published:2014-07-12 Issue:2 Volume:8 Page:145-153
ISSN:1178-1653
Container-title:The Patient - Patient-Centered Outcomes Research
language:en
Short-container-title:Patient

Author:

Stoner Kelly L.,Harder Helena,Fallowfield Lesley J.,Jenkins Valerie A.

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1007/s40271-014-0075-y.pdf

Reference38 articles.

1. Josephson D. Patient preparation and site selection for peripheral IV infusion therapy. Intravenous infusion therapy for nurses: principles and practice. 2nd ed. New York: Thomson Delmare Learning; 2004. p. 143.

2. Shapiro RS. Why I use subcutaneous immunoglobulin (SCIG). J Clin Immunol. 2013;33(Suppl 2):95–8.

3. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:439–46.

4. Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer. 2013;109:1556–61.

5. Mazer M, Chen E. Is subcutaneous administration of rapid-acting insulin as effective as intravenous insulin for treating diabetic ketoacidosis? Ann Emerg Med. 2009;53:259–63.

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial;Digestive and Liver Disease;2024-07

2. Assessing Physicochemical Stability of Monoclonal Antibodies in a Simulated Subcutaneous Environment;Journal of Pharmaceutical Sciences;2024-07

3. Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial;BMJ Open;2024-07

4. Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design;Advanced Drug Delivery Reviews;2024-06

5. Glucans: A Therapeutic Alternative for Sepsis Treatment;Journal of Immunology Research;2024-05-27